Psoriatic Arthritis

Day, Michael S.; Nam, Denis; Goodman, Susan M.; Su, Edwin P.; Figgie, Mark

doi:10.5435/jaaos-20-01-028

Cited by 45 publications

(46 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Mild PsA is typically treated with NSAIDs or intra-articular corticosteroid injections [6,9]. If a satisfactory response is not achieved after 3 months, or if there is evidence of persistent inflammation or of erosive or polyarticular disease, the guidelines suggest the option of using a traditional oral nonbiologic DMARD, such as methotrexate (MTX) [7-9]. Yet the clinical data supporting the use of MTX as a disease-modifying agent in PsA remain limited [10-13].…”

Section: Introductionmentioning

confidence: 99%

Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs

Zhang¹,

Gauthier

Hiscock

et al. 2014

Arthritis Res Ther

View full text Add to dashboard Cite

IntroductionThis study aimed to describe treatment changes (discontinuation, switching, and therapy add-on) following the initiation of biologic or nonbiologic oral disease-modifying antirheumatic drugs (DMARDs) in psoriatic arthritis (PsA) patients.MethodsAdult patients with ≥2 PsA diagnoses from physician office visits, initiated on a biologic or nonbiologic oral DMARD, were selected from the Truven Health Analytics MarketScan® Research Database (2005 to 2009). Patients were required to have continuous insurance coverage ≥6 months prior to and ≥12 months post index date (first prescription fill date). Treatment discontinuation, treatment switch, and therapy add-on were captured over the 1 year period following the index date. Treatment changes were described separately for patients initiated on nonbiologic and biologic DMARDs.ResultsA total of 1,698 and 3,263 patients were initiated on an oral nonbiologic DMARD and biologic DMARD respectively. For patients initiated on nonbiologic DMARDs, 69% had ≥1 therapy change over the 12 month study period (median time 85 days). Among patients who had a therapy change, 83% discontinued, 29% switched therapy (64% switched to a biologic DMARD), and 25% had a therapy add-on (76% added-on with a biologic DMARD). For patients initiated on a biologic DMARD, 46% had ≥1 therapy change (median time 110 days). Among patients who had a therapy change, 100% discontinued, 25% switched therapy (92% switched to another biologic DMARD), and 7% had a therapy add-on with a nonbiologic DMARD.ConclusionThis study suggests that PsA patients newly initiated on a nonbiologic/biologic DMARD do not remain on the index treatment for a long period of time. A better understanding of factors related to these early treatment changes in PsA patients is needed.

show abstract

Section: Introductionmentioning

confidence: 99%

Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs

Zhang¹,

Gauthier

Hiscock

et al. 2014

Arthritis Res Ther

View full text Add to dashboard Cite

show abstract

“…The joint changes in PsA are characterized radiographically by a combination of erosive and proliferative bone changes, including erosive joint destruction, fluffy periostitis, and pencil‐in‐cup deformities 4. Radiographic assessment of joints is recommended to aid in the diagnosis of PsA, provide information on disease severity, and assess the effect of treatment on disease progression 5.…”

mentioning

confidence: 99%

Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis

Heijde

Landewé

Mease

et al. 2016

Arthritis & Rheumatology

View full text Add to dashboard Cite

ObjectiveTo assess whether secukinumab treatment in patients with active psoriatic arthritis (PsA) is associated with sustained inhibition of radiographic progression.MethodsIn this phase III, double‐blind, placebo‐controlled study, 606 patients with PsA were randomized to receive intravenous (IV) secukinumab at a dose of 10 mg/kg (weeks 0, 2, 4) followed by subcutaneous secukinumab at a dose of 150 mg or 75 mg (the IV→150 mg and IV→75 mg groups, respectively) or placebo. Patients were stratified according to prior anti–tumor necrosis factor (anti‐TNF) exposure (71% were anti‐TNF naive). At week 16, placebo‐treated patients who had at least a 20% reduction in the tender and swollen joint counts (responders) continued to receive placebo until week 24; nonresponders were re‐randomized to receive secukinumab at a dose of 150 mg or 75 mg. The modified total Sharp/van der Heijde score (SHS) was determined at baseline, week 16 or 24, and week 52.ResultsIn the overall population, radiographic progression was inhibited through 52 weeks; efficacy was demonstrated for both erosion and joint space narrowing scores and in patients who switched from placebo to secukinumab at week 24. Subgroup analyses showed that secukinumab reduced radiographic progression at week 24, regardless of previous anti‐TNF treatment. Among anti‐TNF–naive patients, the mean changes from baseline to week 24 in the modified total SHS were 0.05 in the pooled secukinumab group and 0.57 in the placebo group; among patients with an inadequate response or intolerance to anti‐TNF treatment, the mean changes were 0.16 and 0.58, respectively. Anti‐TNF–naive patients showed negligible progression through week 52. Inhibition of structural damage was observed through week 52 irrespective of concomitant methotrexate use. A high proportion of patients receiving secukinumab showed no progression (change in SHS of ≤ 0.5) from baseline to week 24 (82.3% of the IV→150 mg group and 92.3% of the IV→75 mg group) and from week 24 to week 52 (85.7% of the IV→150 mg group and 85.8% of the IV→75 mg group).ConclusionSecukinumab inhibited radiographic progression over 52 weeks of treatment in patients with active PsA.

show abstract

“…Препарат представляет собой хи-мерные моноклональные антитела (мАТ), которые блоки-руют растворимые и связанные с цитоплазматической мем-браной молекулы ФНОα [4]. При лечении ПсА препарат можно комбинировать с МТ, обычно используется доза 5 мг/кг внутривенно в начале лечения, на 2-й, 6-й неделях, а затем через каждые 8 нед.…”

Section: общие принципы лечения псаunclassified

“…Диаг-ностика ПсА нередко затруднена вследствие того, что у ча-сти больных превалируют не классические признаки «ис-тинного артрита», а проявления вертебрального пораже-ния, тендинита, энтезита или дактилита. При этом, если псориатическая природа суставного процесса не диагно-стируется своевременно, то, соответственно, не предпри-нимаются адекватные мероприятия по лечению больного, что приводит к прогрессирующему поражению суставов и ранней инвалидизации.Считается, что псориазом страдает примерно от 0,3 до 4,8% населения [4,5]. Среди больных псориазом диа-пазон распространения ПcА достаточно широк: по сооб-щениям разных авторов, он варьирует от 5 до 30% [6,7].…”

unclassified

See 1 more Smart Citation

Current views on the pharmacotherapy of psoriatic arthritis

Тарадин¹,

Ватутин²,

Antonenko³

et al. 2015

RJTAO

View full text Add to dashboard Cite

Псориатический артрит (ПсА) представляет собой хро-ническое серонегативное воспалительное заболевание сус-тавов, ассоциирующееся с кожным псориазом [1][2][3]. Диаг-ностика ПсА нередко затруднена вследствие того, что у ча-сти больных превалируют не классические признаки «ис-тинного артрита», а проявления вертебрального пораже-ния, тендинита, энтезита или дактилита. При этом, если псориатическая природа суставного процесса не диагно-стируется своевременно, то, соответственно, не предпри-нимаются адекватные мероприятия по лечению больного, что приводит к прогрессирующему поражению суставов и ранней инвалидизации.Считается, что псориазом страдает примерно от 0,3 до 4,8% населения [4,5]. Среди больных псориазом диа-пазон распространения ПcА достаточно широк: по сооб-щениям разных авторов, он варьирует от 5 до 30% [6,7]. Рандомизированный телефонный опрос 27 220 жителей США выявил, что в общей популяции встречаемость ПcА составила 0,25%, а среди больных, страдающих псориа-зом, -11% [8]. В 2009 г. в Германии проведено обследова-ние 1511 пациентов с бляшечной формой псориаза, вы-явившее наличие ПсА у 20,6% больных, при этом лишь в 3% случаев суставная патология была диагностирована впервые [9]. (methotrexate, cyclosporine, leflunomide, sulfasalazine), and also a promising group of biologicals. Particular emphasis is placed on the results of using tumor necrosis factor inhibitors (etanercept, infliximab, golimumab, certolizumab pegol, adalimumab), interleukin inhibitors (ustekinumab, brodalumab), and phosphodiesterase 4 inhibitors (apremilast).

show abstract

Psoriatic Arthritis

Cited by 45 publications

References 34 publications

Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs

Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs

Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis

Current views on the pharmacotherapy of psoriatic arthritis

Contact Info

Product

Resources

About